Trial Profile
Nebido Therapy in Hypogonadal Male Patients With Osteoporosis Associated With Paraplegia Compared With Conventional Osteoporosis - Prophylaxis / Therapy in Hypogonadal and Eugonadal Patients With Osteoporosis Associated With Paraplegia.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Apr 2010
Price :
$35
*
At a glance
- Drugs Testosterone undecanoate (Primary)
- Indications Hypogonadism
- Focus Pharmacodynamics
- Sponsors Bayer
- 15 Apr 2010 Planned number of patients changed from 32 to 26 as reported by ClinicalTrials.gov.
- 15 Apr 2010 Actual end date (May 2009) added as reported by ClinicalTrials.gov.
- 15 Apr 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.